1. Home
  2. YMAB vs NEXN Comparison

YMAB vs NEXN Comparison

Compare YMAB & NEXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YMAB
  • NEXN
  • Stock Information
  • Founded
  • YMAB 2015
  • NEXN 2007
  • Country
  • YMAB United States
  • NEXN Israel
  • Employees
  • YMAB N/A
  • NEXN N/A
  • Industry
  • YMAB Biotechnology: Pharmaceutical Preparations
  • NEXN Computer Software: Programming Data Processing
  • Sector
  • YMAB Health Care
  • NEXN Technology
  • Exchange
  • YMAB Nasdaq
  • NEXN Nasdaq
  • Market Cap
  • YMAB 631.1M
  • NEXN 517.8M
  • IPO Year
  • YMAB 2018
  • NEXN 2021
  • Fundamental
  • Price
  • YMAB $11.14
  • NEXN $7.48
  • Analyst Decision
  • YMAB Strong Buy
  • NEXN Strong Buy
  • Analyst Count
  • YMAB 8
  • NEXN 5
  • Target Price
  • YMAB $21.38
  • NEXN $9.30
  • AVG Volume (30 Days)
  • YMAB 268.9K
  • NEXN 79.2K
  • Earning Date
  • YMAB 11-08-2024
  • NEXN 11-15-2024
  • Dividend Yield
  • YMAB N/A
  • NEXN N/A
  • EPS Growth
  • YMAB N/A
  • NEXN N/A
  • EPS
  • YMAB N/A
  • NEXN 0.09
  • Revenue
  • YMAB $84,553,000.00
  • NEXN $349,109,000.00
  • Revenue This Year
  • YMAB $10.24
  • NEXN $7.53
  • Revenue Next Year
  • YMAB $20.21
  • NEXN $7.94
  • P/E Ratio
  • YMAB N/A
  • NEXN $36.48
  • Revenue Growth
  • YMAB N/A
  • NEXN 1.55
  • 52 Week Low
  • YMAB $5.17
  • NEXN $3.37
  • 52 Week High
  • YMAB $20.90
  • NEXN $8.69
  • Technical
  • Relative Strength Index (RSI)
  • YMAB 25.01
  • NEXN 41.17
  • Support Level
  • YMAB $12.47
  • NEXN $7.96
  • Resistance Level
  • YMAB $15.69
  • NEXN $7.71
  • Average True Range (ATR)
  • YMAB 0.97
  • NEXN 0.25
  • MACD
  • YMAB -0.46
  • NEXN -0.07
  • Stochastic Oscillator
  • YMAB 9.88
  • NEXN 18.34

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd empowers advertisers, agencies, publishers, and broadcasters to utilize video and connected TV. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with advanced and exclusive data at its core.

Share on Social Networks: